Please assess the completion status of the following clinical trial:

Trial Title: Trial to Compare the Routes of Administration of an Investigational, Personalized, Therapeutic Cancer Vaccine Oncophage (HSPPC-96) in Patients With Metastatic Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Suspected metastatic renal cell carcinoma (AJCC Stage IV) with intact primary tumor~* No previous therapy for metastatic renal cell carcinoma~* Measurable disease (RECIST criteria)~* Primary tumor greater than or equal to 7cm on CT or MRI~* ECOG performance status 0-1~* At least 18 years old~* Life expectancy \> 3 months~* Adequate cardiac function (NYHA I-II)~* Not pregnant~* Provide written informed consent~* Absence of multiple liver metastases, brain or threatening bone metastases (axial skeleton and/or pathological features)~* Planned complete nephrectomy~Exclusion Criteria:~* History of primary or secondary immunodeficiency, or patients using systemic corticosteroids or cyclosporin A~* Other cancer (including renal cell carcinoma) within the last five years (with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin)~* Embolization of the renal artery prior to nephrectomy~* Active, uncontrolled infection or other serious medical illnesses, preventing study completion, in the opinion of the Principal Investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).